Semaglutide vs. Tirzepatide: Which GLP-1 Is Right for Your Goals
Two molecules, two mechanisms, one decision.
"They look like the same idea wearing two different coats. Under the hood, they are not the same drug, and the gap shows up on the scale."
Walk into any conversation about GLP-1 medicines and two names surface within a minute. Semaglutide, sold as Ozempic and Wegovy. Tirzepatide, sold as Mounjaro and Zepbound. People tend to treat them as interchangeable. They are not. One pulls a single lever in your metabolism. The other pulls two. That difference is small on paper and surprisingly large in the mirror.
For a microdose protocol the choice matters even more, because you are working with a smaller signal and you want every fraction of a milligram pointed at the goal that actually matters to you.
MicrodoseGLPs Research Team
Evidence based metabolic health optimization
One Lever or Two
Your gut releases hormones called incretins after you eat. They tell the pancreas to release insulin, slow how fast the stomach empties, and quiet appetite signals in the brain. Semaglutide mimics one of these hormones, GLP-1. It is a clean, single-target agonist, and it works well.
Tirzepatide does something newer. It activates the GLP-1 receptor and a second incretin receptor called GIP at the same time. That dual action is why it is often called a "twincretin." The two pathways reinforce each other, improving how the body handles glucose and how strongly it suppresses appetite.
Single agonist. Boosts insulin, slows gastric emptying, curbs appetite.
Dual agonist. Engages GIP more strongly than GLP-1 — an imbalanced dual mechanism that reinforces both pathways.
What SURMOUNT-5 Settled
For years the two drugs were only compared indirectly, trial against separate trial. Then in May 2025 the New England Journal of Medicine published SURMOUNT-5, the first head to head study, putting 751 adults with obesity and no diabetes on the maximum tolerated dose of one drug or the other for 72 weeks. The result was not close.
Average Weight Loss at 72 Weeks
SURMOUNT-5 — maximum tolerated dose, adults with obesity. Source: Aronne et al., NEJM 2025.
13.7%
Semaglutide — ≈33 lb
20.2%
Tirzepatide — ≈50 lb
Share of Patients Hitting Weight Loss Targets
The advantage widens at the most demanding thresholds. Source: SURMOUNT-5.
- Semaglutide
- Tirzepatide
About 1 in 3 people on tirzepatide lost at least 25% of body weight. On semaglutide it was closer to 1 in 6. Waist circumference fell further too: 18.4 cm vs. 13.0 cm.
If Your Goal Is Glucose
Weight is only half the story. For people managing type 2 diabetes, the question is HbA1c, the rolling average of blood sugar. Here too the dual mechanism shows up. In the SURPASS-2 trial and in large real world datasets, tirzepatide lowered HbA1c more than semaglutide, and a notable share of patients dropped into the normal, non-diabetic range.
Real-World Change at 12 Months
GLP-1 naive patients with type 2 diabetes. Source: HIRD real-world cohort.
- Semaglutide
- Tirzepatide
Where Semaglutide Still Wins
None of this means tirzepatide is simply the better drug for everyone. Semaglutide has the longer track record, broader insurance familiarity, more established cardiovascular and kidney outcome data, and an approved oral tablet form. For a gentler entry point, or for someone whose goal is steady appetite control rather than maximum loss, it remains an excellent and often more accessible choice.
Side by Side, at a Glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand names | Ozempic, Wegovy | Mounjaro, Zepbound |
| Mechanism | Single GLP-1 agonist | Dual GIP + GLP-1edge |
| Avg. weight loss (72 wk) | 13.7% | 20.2%edge |
| HbA1c lowering | Strong | Strongestedge |
| Most common GI effect | Nausea, constipation | Diarrhea, less nausea |
| GI dropouts (trial) | 5.6% | 2.7%edge |
| Oral form available | Yes (tablet)edge | Injection only |
| Track record | Longer, broaderedge | Newer, growing |
| Dosing frequency | Once weekly | Once weekly |
Edges mark a general directional advantage from current evidence, not a recommendation. Tolerability is individual.
Translating This to Small Doses
Standard protocols titrate up to high therapeutic doses. A microdose approach does the opposite: it starts well below the usual entry point and moves slowly, trading speed for tolerability and cost. Both molecules can be microdosed, and the goal shapes the choice.
Semaglutide (Ozempic / Wegovy)
Tirzepatide (Mounjaro / Zepbound)
Across surveys, a large share of GLP-1 users stop within the first year — cost and side effects the two leading reasons. A drug only works while you are still taking it. The "better" molecule is the one whose results, tolerability, and price you can actually sustain.
The Honest Summary
Tirzepatide tends to lose more. Semaglutide tends to be easier to reach for. The right answer is the goal, not the molecule.
Frequently Asked Questions
References
- Aronne LJ, et al. Tirzepatide vs Semaglutide for Obesity (SURMOUNT-5). New England Journal of Medicine, 2025.
- Obesity Medicine Association. Tirzepatide vs Semaglutide: A Comprehensive Comparison for Providers, 2026.
- American College of Cardiology. SURMOUNT-5: Greater Loss of Weight and Waist Circumference, 2025.
- Frias JP, et al. SURPASS-2: Tirzepatide vs Semaglutide in Type 2 Diabetes. NEJM, 2021.
- Real World Effectiveness of Tirzepatide vs Semaglutide on HbA1c and Weight. HIRD cohort, PMC, 2025.
This article is educational and not medical advice. GLP-1 medications are prescription drugs. Microdosing is an off-label, non-FDA-approved use and should only be done under the supervision of a licensed clinician who can assess your history, monitor labs, and adjust your plan.
Find the Protocol That Fits Your Goal
Answer a few questions and get a personalized starting point — molecule, dose, and tracking rhythm.
Find Your Protocol